Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3435151
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LY3435151 is an investigational monoclonal antibody developed by Eli Lilly that targets CD226 (also known as DNAX accessory molecule-1 or DNAM-1), a cell surface glycoprotein expressed on immune cells. It acts as an agonist of CD226, with the aim of stimulating antitumor immune responses. The drug was designed for intravenous administration and was evaluated in early-phase clinical trials for advanced solid tumors. Its mechanism involves binding to and activating CD226, potentially enhancing the activity of T cells and natural killer (NK) cells against cancer cells. Development was discontinued after phase 1 trials due to strategic business decisions[1][2][3][4][5].
- Other names
- anti-CD226 agonist antibody LY3435151anti-CD-226 agonist antibody LY3435151anti-CD 226 agonist antibody LY3435151
02
Targets
CD226 (DNAX accessory molecule 1)
Beyond the preview
Go deeper on LY3435151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3435151.